Previous 10 | Next 10 |
Palisade Bio ( NASDAQ: PALI ) stock rose ~7% after the company said that the European Patent Office (EPO) will grant it a patent linked to its drug LB1148 for reducing post-surgical abdominal adhesions The EPO issued a notice of intention to grant for patent application numbe...
Carlsbad, CA, March 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that European Patent Office (EPO) ...
Biopharmaceutical company Palisade Bio ( NASDAQ: PALI ) promoted Senior Vice President, Operations and Strategic Development, Robert McRae to the post of COO. Additionally, Interim CEO J.D. Finley has been appointed to the board. PALI shares were trading ~3% ...
Mr. McRae is an i ndustry veteran with a proven track record of operational , clinical , and strategic business development execution Carlsbad, CA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clini...
- Live video webcast presentations with participating companies - FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, Jan...
Proceeds expected to extend cash runway to fund operations into the second half of 2024 Carlsbad, CA, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic ga...
Live video webcast on Tuesday, January 17 th at 3:00 PM ET Carlsbad, CA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, to...
Carlsbad, CA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has closed its previously announced registered direct...
3 Tips for Trading Penny Stocks in 2023 Penny stocks, or stocks that trade for less than $5 per share, can be a high-risk, high-reward investment. Because penny stocks are generally not as well known as blue chips, they can be more volatile and may fluctuate significantly in price. Howeve...
3 Ways to Improve Your Chances of Profitability With Penny Stocks Having consistent gains when investing in penny stocks is critical due to the volatile nature of the stock market. The price of penny stocks can fluctuate rapidly and you may end up losing your investment if you are not car...
News, Short Squeeze, Breakout and More Instantly...
Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition o...
Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Ph...
Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel...